Company intelligence / Profile preview

Shanghai Kanda Biotechnology

Shanghai, Shanghai Shi, Chinakandatech.cn ↗

Ownership: Private
Development stage: Other

Overview

Shanghai Kanda Biotechnology has developed monoclonal antibodies targeting CTLA4 with a completed Phase 1 trial in advanced solid tumors. The company also holds patents for fusion proteins targeting the TACI–BAFF pathway for autoimmune and hematological indications. No published late-stage clinical results were identified; early-phase safety/tolerability data have been generated in oncology settings.

Therapeutic areas: OncologyImmunologyHematology
Modalities: Monoclonal antibodyFusion proteinProtein
Industry: Biotech

Drug pipeline

1 asset

KD6001

Partnerships

Shanghai Celgen Bio-pharmaceutical Co., Ltd. [collaborator/sponsor of KD6001 trial]

Beyond the preview

Go deeper on Shanghai Kanda Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Kanda Biotechnology.